Skip to main content

Type 2 Diabetes Prevalence Rose in the United States From 2012 to 2022

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 25, 2024.

By Lori Solomon HealthDay Reporter

FRIDAY, Aug. 23, 2024 -- The prevalence of diabetes increased in the United States from 2012 to 2022, according to a research letter published online July 18 in Diabetes, Obesity and Metabolism.

Sulakshan Neupane, from the University of Georgia in Athens, and colleagues examined recent national trends and disparities in self-reported diabetes prevalence among U.S. adults. The analysis included 5.3 million participants in the Behavioral Risk Factor Surveillance System (2012 to 2022).

The researchers found that the overall prevalence of diabetes increased significantly by 18.6 percent during the study period, across all sociodemographic groups. The prevalence was highest among non-Hispanic Black people (15.8 percent) and individuals aged 65 years and older (23.86 percent). Compared with non-Hispanic White individuals, odds were higher among Hispanic individuals (adjusted odds ratio [aOR], 1.60), non-Hispanic Asians (aOR, 1.67), and non-Hispanic Black individuals (aOR, 2.10). Men had a slightly higher prevalence than women (12.56 versus 11.56 percent). Prevalence was 56 percent higher among individuals with lower incomes. Individuals with obesity faced the highest prevalence -- 19.23 percent -- compared with individuals with normal weight.

"This study showed significant increases in diabetes prevalence across the United States from 2012 to 2022, aligning with previous research demonstrating rising trends nationally over recent decades," the authors write. "Persistently high and increasing prevalence underscores the alarming diabetes epidemic facing the United States."

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Real-World Weight Loss With Semaglutide, Tirzepatide Less Than That Seen in Clinical Trials

THURSDAY, June 12, 2025 -- For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower...

Increasing Proportion of U.S. Adults Unaware They Have Hypertension

MONDAY, June 9, 2025 -- From 2013 to 2023, there was an increase in the proportion of U.S. adults who were unaware of having hypertension, according to a research letter published...

Finerenone + Empagliflozin Offers Greater Benefit in CKD, T2DM

MONDAY, June 9, 2025 -- For patients with chronic kidney disease and type 2 diabetes, combination finerenone plus empagliflozin leads to a greater reduction in the urinary...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.